Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
about
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsHigh prevalence of illicit drug use in men who have sex with men with HIV-1 infection in JapanWeek 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patientsDrug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic StudyChange in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialWHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort studyEffect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo.Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients.
P2860
Q28535587-D00574C8-37FF-45E8-B9D9-D159AD51DE72Q28536725-9C0A229F-5790-4665-B82E-EBC87E23049DQ28545183-9FD3FB4C-6E4F-484A-871B-3ED4AC2435EAQ28550681-1977DEB9-B116-4958-8563-C6677F2388D7Q33734997-A6658EC6-2235-4DF8-B07F-8B0D07FA14BAQ33799767-C58668B8-E34C-4F51-8752-C0AA9721D548Q34952127-60D0EE9C-CC71-4734-811D-95D567F18468Q35040358-BBBD0548-59CD-4E31-9EED-6B7BAE1213A5Q35071954-726A40DB-436D-4B1E-B858-C695C6E222DDQ35134488-58578B64-D305-4CA2-8FF4-FC08DF33F035Q35149475-770E1591-1FF5-4ACC-8820-CD59A5D23537Q36237157-960F0DF1-FC63-4E03-87EC-914F9506C6D1Q36576316-58B35CF9-04BF-4556-9EC5-047C37CD3F58Q36955003-78078687-C124-4CFC-862A-BEF802E49484Q37278399-36437054-74D1-45CA-B90C-CFDC5F6DEE17Q37713060-DD93CB52-68A9-4A1A-964B-7056E9DD2BA5Q38798813-DEA211C0-DA36-4CCA-9A19-F6511A6FC873Q40497483-02ADA6F9-6ABF-4A50-B5BE-F3D046D289D9Q40541589-0AE56775-7EAD-44F1-A303-5C0D8D94CCD9Q41128689-7A3DC386-CC21-4EFE-BAA9-7B37D1905527Q41428022-30AC4C45-F380-4D51-8A92-6AD1B5AF378BQ47151132-B424BDB5-5419-4ADE-8EC5-CA0DD35D8FB7Q55303657-A4A06358-0D42-4EF3-8D5C-DFFA7D2BC80A
P2860
Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Renal function declines more i ...... e patients with HIV infection.
@ast
Renal function declines more i ...... e patients with HIV infection.
@en
Renal function declines more i ...... e patients with HIV infection.
@nl
type
label
Renal function declines more i ...... e patients with HIV infection.
@ast
Renal function declines more i ...... e patients with HIV infection.
@en
Renal function declines more i ...... e patients with HIV infection.
@nl
prefLabel
Renal function declines more i ...... e patients with HIV infection.
@ast
Renal function declines more i ...... e patients with HIV infection.
@en
Renal function declines more i ...... e patients with HIV infection.
@nl
P2093
P2860
P1433
P1476
Renal function declines more i ...... e patients with HIV infection.
@en
P2093
Haruhito Honda
Hirokazu Komatsu
Hiroyuki Gatanaga
Junko Tanuma
Katsuji Teruya
Koji Watanabe
Kunihisa Tsukada
Miwako Honda
Shinichi Oka
P2860
P304
P356
10.1371/JOURNAL.PONE.0029977
P407
P577
2012-01-05T00:00:00Z